Bladder cancer is the most common malignant tumor of the urinary tract. Novel treatment approaches are essential because of the failure of current treatment options to cure a high percentage of patients. Telomerase, a ribonucleoprotein, is detected in almost all bladder cancer, but not in normal bladder tissues. Therefore, telomerase is expected to be a very promising candidate for targeted therapy of bladder cancer. In this study, we synthesized a 19-mer antisense oligonucleotide against the RNA component of human telomerase (hTR) linked to a 2-5A molecule (2-5A-anti-hTR) and investigated its antitumor effect against bladder cancer cells. The 2-5A antisense strategy relies on the recruitment and activation of RNase L at the site of targeted RNA Keywords: 2-5A; antisense; telomerase; bladder cancer; apoptosis
In 1998 it was estimated that the number of new cases of bladder cancer would be greater than 54 000 and approximately 12 500 bladder cancer deaths would occur in the United States. 1 Superficial tumors including carcinoma in situ can be cured by transurethral resection and/or intravesical instillation of bacillus Calmette-Guérin vaccine (BCG). 2, 3 However, 15% of these tumors progress to muscle-invasive cancer and required cystectomy. 4, 5 In contrast with superficial tumors, the prognosis of advanced bladder cancer is poor and the 5-year survival rate is about 50% even after the radical surgical excision. 6 Therefore, in order to improve prognosis of bladder cancer, it is absolutely essential to explore a novel modality of treatment.
Telomerase is a ribonucleoprotein enzyme that elongates telomeric DNA at the ends of chromosomes. 7 Most normal cells do not have the enzyme and lose telomeric DNA with each mitotic cycle, resulting in senescence or cell death. 7, 8 By contrast, approximately 90% of tumors of wide range express telomerase and can continue to proliferate. [9] [10] [11] Recent investigations demonstrate that telomerase activity is detected in more than 90% of bladder cancer, but not in normal bladder tissues. 12, 13 sequence. Here we demonstrate that treatment with 2-5A-anti-hTR reduced the viability of seven bladder cancer cell lines (UM-UC-2, UM-UC-3, UM-UC-6, UM-UC-9, UM-UC-14, RT4 and T24) expressing telomerase activity to 21-55% within 4 days. The cytotoxicity was mainly due to induction of caspase-dependent apoptosis. In contrast, normal fibroblast WI38 cells lacking telomerase activity were resistant to the treatment. Furthermore, treatment of subcutaneous UM-UC-2 tumors in nude mice with 2-5A-anti-hTR significantly suppressed the tumor growth through induction of apoptosis (P Ͻ 0.001). These findings may offer a strong support to the feasibility of the 2-5A-anti-hTR treatment for human bladder cancer. Gene Therapy (2001) 8, 654-658.
telomerase may be a very promising candidate for targeted therapy of bladder cancer. Recently, we have synthesized an antisense oligonucleotide against human telomerase RNA component (hTR) linked 2-5A (5Ј-phosphorylated 2Ј-5Ј-linked oligoadenylate) (2-5A-anti-hTR) and demonstrated its cytotoxic effect on human malignant glioma cells in vitro and in vivo.
14,15 2-5A is a mediator of one pathway of interferon actions. 2-5A activates RNase L that is ubiquitous in mammalian cells, resulting in single-stranded RNA cleavage after UN sequences. 16, 17 Antisense against a certain target linked to 2-5A causes degradation of the targeted RNA in a highly specific manner, and enhances the potency of antisense at least 20-fold. [18] [19] [20] The antitumor effect of 2-5A-anti-hTR is specific for telomerasepositive cells. It is therefore expected that telomerasepositive bladder cancer cells are also sensitive to the 2-5A-anti-hTR treatment. In this study, we investigated the antitumor efficacy of 2-5A-anti-hTR against bladder cancer cells in vitro and in vivo.
We initially investigated whether bladder cancer cell lines (UM-UC-2, UM-UC-3, UM-UC-6, UM-UC-9, UM-UC-14, T24, and RT4) ( a kind gift from Dr H Barton Grossman, University of Texas MD Anderson Cancer Center, Houston, TX, USA) have telomerase activity using the telomeric repeat amplification protocol (TRAP) assay as described previously. 14, 15 As shown in Figure 1 , telomerase activity was clearly detected in all tumor cell lines we tested. In contrast, fibroblast WI38 cells did not express the activity. The internal telomerase activity stan- dard (ITAS) was detected in extracts from all cell lines, which excluded the possibility of a false negative result due to Taq polymerase inhibitors. Therefore, when we examined the effect of 2-5A-anti-hTR on bladder cancer cells, WI38 cells were used as a control of telomerasenegative cells.
Next, seven bladder cancer cell lines described above were treated with the 2-5A-linked, 19-mer antisense against telomerase RNA (spA 4 -anti-hTR) as described previously.
14,15 As a control, spA 4 -anti-(M6)hTR having an active 2-5A moiety, but six mismatches in the antisense molecule was used. To enhance the transduction efficiency of 2-5A-anti-hTR oligonucleotide, a cationic liposome, lipofectamine was mixed with oligonucleotides before the treatment. Since the ratio of 2-5A-anti-hTR oligonucleotide to lipofectamine was important for efficient transduction, we first optimized and determined that the treatment with 2-5A-anti-hTR (0.5 m) in the presence of lipofectamine (0.4 l/100 l DMEM) was better than other ratios (data not shown). Therefore, we treated all cells at this ratio. As shown in Figure 2 , treatment with spA 4 -anti-hTR for 4 days reduced the viability of bladder cancer cells to 21-55% in all cell lines. UM-UC-14 and RT4 cells were relatively resistant to the treatment when compared to the other five cancer cells. The cytotoxic effect of mismatch spA 4 -anti-(M6)hTR oligonucleotide was much less when compared to the test oligonuclotide, spA 4 -anti-hTR. The cell viability of WI38 cells lacking telomerase activity treated with spA 4 -anti-hTR or spA 4 -anti-(M6)hTR was 88 or 86%, respectively. These results indicated that 2-5A-anti-hTR was specifically effective for telomerase-positive cells, but not for telomerase-negative cells. Furthermore, to validate the specificity of 2-5A-anti-hTR treatment in bladder cancer cells, the change of telomerase activity was examined. As shown in Figure 3 , the spA 4 -anti-hTR treatment for 4 days significantly inhibited the telomerase activity to 75% when compared with the lipofectamine alone or spA 4 -anti-(M6)hTR treatment (P Ͻ 0.05, respectively). Previously, we demonstrated that the 2-5A-anti-hTR treatment specifically degrades hTR 5 hr later.
14 These findings indicated that the 2-5A-anti-hTR treatment degraded hTR and consequently suppressed telomerase activity.
To investigate whether 2-5A-anti-hTR induced apoptosis in bladder cancer cells, we used the terminal deoxynucleotidyl transferase (Tdt)-mediated nick end labeling (TUNEL) assay. Figure 4A shows TUNEL staining of UC2 cells after 3 days treatment. The cells treated with Lipofectamine alone showed very few stained cells (Figure 4Aa ). In contrast, most of the cells treated with spA 4 -anti-hTR stained strongly (Figure 4Ab) . To quantify the extent of apoptosis, the percentage of TUNEL-positive cells from a total 250 cells was determined in each Gene Therapy
Figure 4 Apoptotic features of UM-UC-2 cells. 5 × 10
4 cells were seeded in a well of six-well plates, and treated with a 0.5 m oligonucleotide mixed with lipofectamine (4 l/ml) every 24 h for 3 days. The ApopTag kit (Oncor Inc.) was used as described previously.
14,22 (A) TUNEL staining of the cells treated every 24 h for 3 days with (a) Lipofectamine alone and (b) spA 4 -anti-hTR. Arrows show representative cells with positive staining. Bar, 100 m. (B) Quantification of TUNEL-positive cells during the treatment of UM-UC-2 cells for 3 days. The percentage of TUNEL-positive cells was counted in 250 cells 1, 2, and 3 days after treatment. Results are the means ± s.d. of three independent experiments.
treatment group. As shown in Figure 4B , the percentage of apoptotic cells after the spA 4 -anti-hTR treatment was increased in a time-dependent manner. The percentage of TUNEL-positive UM-UC-2 cells at days 1, 2 and 3 was 8, 28, and 68%, respectively. In contrast, 13 or 5% cells were TUNEL-positive after the 3-days treatment with control oligonucleotide spA 4 -anti-(M6)hTR or lipofectamine alone, respectively. These results indicated that the cytotoxic effect of 2-5A-anti-hTR was mainly due to induction of apoptosis.
Because caspases are the main factors in the apoptotic pathway, we investigated whether caspases were involved in the antitumor effect of 2-5A-anti-hTR using caspase inhibition assays. The treatment with spA 4 -antihTR was performed in the presence of caspase inhibitors. After the treatment for 4 days, the viability of UM-UC-2 cells was reduced to 28% ( Figure 5 ). The addition of ICE (caspase 1) or CPP32 (caspase 3) inhibitor (100 m) recovered the viability of UM-UC-2 cells to 78 or 75% (P Ͻ 0.01 compared with spA 4 -anti-hTR alone, respectively). These results indicated the involvement of caspase family (at least ICE and CPP32) in the induction of apoptosis by the 2-5A-anti-hTR treatment.
To investigate the in vivo effect of treating tumors with spA 4 -anti-hTR, UM-UC-2 cells were subcutaneously inoculated into nude mice. When the tumors reached a mean volume of 60-80 mm 3 , they received daily injections of spA 4 -anti-hTR or spA 4 -anti-(M6)hTR mixed with lipofectamine, respectively. After the spA 4 -anti-hTR treatment for 7 days, the size of the UM-UC-2 tumors was reduced to 81.9% when compared with the initial size ( Figure 6A ). On the other hand, the percentage of increase in tumor volume treated with lipofectamine alone or spA 4 -anti-(M6)hTR was 207 or 88%, respectively. As shown in Figure 6Bc , many apoptotic cells were detected in the tumor specimens treated with spA 4 -antihTR. In contrast, few cells were stained in the control tumors treated with lipofectamine alone or spA 4 -anti-(M6)hTR (Figure 6Ba or b) , respectively. These results indicated that the treatment with 2-5A-anti-hTR significantly suppressed the in vivo growth of bladder cancer through apoptosis induction. It may be difficult to detect all cells undergoing apoptosis during the treatment the next day after the last treatment because it is likely that apoptotic cells induced by 2-5A-anti-hTR are soon eliminated by phagocytotic cells. However, it may be important to verify how efficiently 2-5A-anti-hTR can get into the target and block the hTR expression. Therefore, further studies using tissue samples collected every day during the 1 week treatment may be necessary.
Because telomerase activity is detected in a vast majority of tumors, but not in most normal cells, [7] [8] [9] [10] [11] it is expected that inhibition of telomerase function may alter the growth properties of tumor cells and subsequently suppress the tumor growth. 23, 24 Since the RNA component of human telomerase (hTR) was first known, 25 several trials that target hTR with antisense RNA, [25] [26] [27] hammerhead ribozyme 28 or peptide nucleic acids 29 were reported. They reduced telomerase activity and tumor growth to some extent. Recently, additional two components of the human telomerase were identified: the telomerase-associated protein (TEP1) 30, 31 and the telomerase catalytic subunit or telomerase reverse transcriptase (hTERT). 32, 33 Although hTR and hTERT are essential for telomerase activity, the expression of hTERT is closely associated with telomerase activity. 34, 35 Therefore, to inhibit telomerase activity significantly, the hTERT may be more attractive as a target than the hTR. More recently, it has been demonstrated that the complete inhibition of telomerase using a dominant-negative mutant of hTERT resulted in reduction in telomere length and apoptotic cell death of tumor cells. 24, 36, 37 When the tumors with short telomere are treated, inhibition of hTERT function may be effective. On the other hand, 2-5A-anti-hTR induced caspase-dependent apoptosis in tumor cells. Although it took about 1 month for U251-MG cells to undergo apoptosis following the complete inhibition of telomerase activity, 26 treatment with 2-5A-anti-hTR induced apoptosis in a majority of these tumor cells within 4 days. 15 As described in the present study,
Gene Therapy 68% of bladder cancer UM-UC-2 cells underwent apoptosis 3 days after the initiation of treatment. The time course for cell death induced by 2-5A-anti-hTR is very fast relative to the expected rate of telomere shortening. These results suggested one possibility that the effect of 2-5A-anti-hTR may be independent of telomere length in tumor cells. If the mechanism underlying the effect of 2-5A-anti-hTR is actually independent of telomere length, the approach has much greater potential application. Therefore, further studies are necessary to determine the telomere length after the 2-5A-anti-hTR treatment.
As the fifth most common cause of non-skin cancer in men and women in the United States, bladder cancer is a very important public health problem. [1] [2] [3] [4] [5] Despite advances in radical surgery or adjuvant chemotherapy, the 5-year survival rate for patients with invasive cancer is still about 50%. 6 Because telomerase is detected in more than 90% of bladder cancer, but not in normal bladder tissues, 12, 13 we expect that 2-5A-anti-hTR is a promising therapeutic agent for the treatment of bladder cancer.
